FDA’s Graham Casts Doubt On Naproxen Cardioprotection, Vioxx Defense
This article was originally published in The Tan Sheet
Executive Summary
Debate during a three-day panel meeting on the safety of COX-2s and NSAIDs appeared to reach a consensus that naproxen carries little to no cardioprotective benefit